OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen
2006 · The Journal of Immunology · 105 citations
https://doi.org/10.4049/jimmunol.176.2.974
P
Peter Kim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
37
Papers
1.3K
Citations
11
h-index
12
i10-index
Peter Kim is an academic researcher from AVEO Oncology (United States). The author has contributed to research in topics: CAR-T cell therapy research & Synthesis and Biological Evaluation & Multiple Myeloma Research and Treatments. The author has an h-index of 11, co-authored 32 publications.
ORCID: 0000-0003-4108-299XPapers by this author
worksPre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
2024 · Cells · 11 citations
https://doi.org/10.3390/cells13100879
Supplementary Figure 4 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25392855
Supplementary Table 1 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25392849.v1
Supplementary Figure 3 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25392858.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat